Human papillomavirus infection and the primary and secondary prevention of cervical cancer

Cancer

Volumn 113, Issue 7, 2008, Pages 1980-1993

  Lowy, Douglas R ^a   Solomon, Diane ^a   Hildesheim, Allan ^a   Schiller, John T ^a   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical intraepithelial lesion; Developing world; Human papillomavirus assays; Papanicolaou smear; Screen and treat approach; Virus like particle vaccines

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPANICOLAOU TEST; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DIAGNOSIS; VIRUS INFECTION; WART VIRUS;

FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; ONCOGENES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS;

EID: 53949091845     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23704     Document Type: Review

References (108)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
3. Chan S-Y, Ho L, Ong C-K, et al. Molecular variants of human papillomavirus-16 from 4 continents suggest pandemic spread of the virus and its coevolution with humankind. J Virol. 1992;66:2057-2066.
4. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-285.
5. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337:76-84.
6. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
7. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(suppl 1): S16-S24.
8. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1796-1807.
9. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-1836.
10. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119:2677-2684.
11. Palefsky JM, Holly EA. Chapter 6: immunosuppression and coinfection with HIV. J Natl Cancer Inst Monogr. 2003;(31):41-46.
12. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582-1589.
13. Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004;321:205-216.
14. Bishop B, Dasgupta J, Klein M, et al. Crystal structures of 4 types of human papillomavirus Ll capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem. 2007;282:31803-31811.
15. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513-517.
16. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
17. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev. 2007;16:4-10.
18. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119:1108-1124.
19. Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481-1495.
20. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8097 women with squamous cell carcinoma and 1374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885-891.
21. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
22. Howley PM, Lowy DR. Papillomaviruses. In: Knipe DM, Howley PH, eds. Fields Virology, 5th ed, vol 2. Philadelphia: Lippincott Williams & Wilkins; 2007:2299-2354.
23. Song S, Liem A, Miller JA, Lambert PE Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology. 2000;267:141-150.
24. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci. 2008;13:1003-1017.
25. Hampl M, Wentzensen N, Vinokurova S, et al. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol. 2007;133:235-245.
26. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
27. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002; 94:1406-1414.
28. Zuna RE, Wang SS, Rosenthal DL, Jeronimo J, Schiffman M, Solomon D. Determinants of human papillomavirusnegative, low-grade squamous intraepithelial lesions in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). Cancer. 2005;105:253-262.
29. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
30. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer. 1999;80:2008-2018.
31. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004; 78:11451-11460.
32. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol. 2006;208:152-164.
33. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res. 2004;10:3059-3063.
34. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991;65:606-612.
35. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307-313.
36. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA. 1995;92:1654-1658.
37. Vaccarella S, Franceschi S, Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15:326-333.
38. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-2654.
39. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis. 2007;196:1137-1145.
40. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-1112.
41. Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004;31:601-607.
42. Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Philadelphia, Pa: Saunders; 2008.
43. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395-403.
44. Mast EE, Ward JW. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Philadelphia: Saunders; 2008:205-241.
45. Robbins JB, Schneerson R, Szu SC. Hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171:1387-1398.
46. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol. 2003;21:515-546.
47. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller IT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000;270:254-257.
48. Lowy DR, Schiller IT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167-1173.
49. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235-270.
50. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller IT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996;70:3298-3301.
51. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent Ll virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.
52. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
53. loura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 3 randomised clinical trials. Lancet. 2007;369:1693-1702.
54. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of 4 randomised clinical trials. Lancet. 2007;369:1861-1868.
55. Harper DM, Franco EL, Wheeler C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
56. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.
57. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298:743-753.
58. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
59. Kirnbauer R, Chandrachud L, O'Neil B, et al. Virus-like particles of Bovine Papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996;219:37-44.
60. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652-1661.
61. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
62. Freeman H, Wingrove B. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. NIH Pub. No. 05-5282. Rockville, Md: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005.
63. Orenstein WA, Rodewald LE, Hinman AR, Schuchat A. Immunization in the United States. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Philadelphia: Saunders; 2008:1479-1510.
64. French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer. 2007;96:514-518.
65. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data. 2005;(362):1-55.
66. Schiller JT, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine. 2006;24(suppl 3):S147-S153.
67. Nardelli-Haefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine. 2005;23:3634-3641.
68. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14:1285-1295.
69. Maclean J, Koekemoer M, Olivier AJ, et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol. 2007;88(pt 5):1460-1469.
70. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol. 1998;72:6151-6154.
71. Yuan H, Estes PA, Chen Y, et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol. 2001;75:7848-7853.
72. Chandrachud LM, Grindlay GJ, McGarvie GM, et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 1995;211:204-208.
73. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with antisera to the amino terminus of L2. Virology. 2005;337:365-372.
74. Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol. 2007;81:11585-11592.
75. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(suppl 3):S171-S177.
76. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer. 2008;98:15-21.
77. Schiffman M, Castle PE. The promise of global cervicalcancer prevention. N Engl J Med. 2005;353:2101-2104.
78. Solomon D. Chapter 14: role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr. 2003;(31):97-101.
79. Biscotti CV, Dawson AE, Dziura B, et al. Assisted primary screening using the automated ThinPrep imaging system. Am J Clin Pathol. 2005;123:281-287.
80. Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2006;367:122-132.
81. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008;111:167-177.
82. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
83. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7:547-555.
84. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774.
85. Casde PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1-e6.
86. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-345.
87. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355.
88. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23:315-330.
89. Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007;13:2599-2605.
90. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer:5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-1772.
91. Mayrand MH, Duarte-Franco E, Rodrigues 1, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
92. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-1597.
93. Ronco G, Segnan N. HPV testing for primary cervical cancer screening. Lancet. 2007;370:1740-1742.
94. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing. A summary of meta-analyses. Vaccine. 2006;24(suppl 3):S78-S89.
95. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
96. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99(3suppl 1):S7-11.
97. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Costeffectiveness of cervical-cancer screening in 5 developing countries. N Engl J Med. 2005;353:2158-2168.
98. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398-406.
99. QIAGEN NV PR Newswire. Study finds new version of QIAGEN's HPV test for developing countries could reduce risk of cervical cancer by more than half when combined with appropriate treatment. Biomedicine. November 7, 2007:1-6.
100. Jeronimo J, Castle PE, Herrero R, Burk RD, Schiffman M. HPV testing and visual inspection for cervical cancer screening in resource-poor regions. Int J Gynaecol Obstet. 2003;83:311-313.
101. Mariategui J, Santos C, Taxa L, Jeronimo J, Castle PE. Comparison of depth of necrosis achieved by CO- and NO-cryotherapy. Int J Gynaecol Obstet. 2008;100:24-26.
102. Seamans Y, Loesel C, Jeronimo J, Sellors J, Castle PE. Effect of cough technique and cryogen gas on temperatures achieved during simulated cryotherapy [abstract]. BMC Womens Health. 2007;7:16.
103. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145-153.
104. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66:10112-10119.
105. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol. 2006;195:349-353.
106. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006;108:264-272.
107. Jeronimo J, Massad LS, Castle PE, Wacholder S, Schiffman M. Interobserver agreement in the evaluation of digitized cervical images. Obstet Gynecol. 2007;110:833-840.
108. Jeronimo J, Massad LS, Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type [serial online]. Am J Obstet Gynecol. 2007;197:47.e1-e8.